Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity
Identifieur interne : 000340 ( Pmc/Curation ); précédent : 000339; suivant : 000341Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity
Auteurs : Kimberley A. Walsh [Canada] ; Joseph F. Megyesi [Canada] ; John X. Wilson [Canada] ; Jeff Crukley [Canada] ; Victor E. Laubach [États-Unis] ; Robert R. Hammond [Canada]Source :
- Journal of Neuroinflammation [ 1742-2094 ] ; 2004.
Abstract
The pathogenesis of HIV-1 glycoprotein 120 (gp120) associated neuroglial toxicity remains unresolved, but oxidative injury has been widely implicated as a contributing factor. In previous studies, exposure of primary human central nervous system tissue cultures to gp120 led to a simplification of neuronal dendritic elements as well as astrocytic hypertrophy and hyperplasia; neuropathological features of HIV-1-associated dementia. Gp120 and proinflammatory cytokines upregulate inducible nitric oxide synthase (iNOS), an important source of nitric oxide (NO) and nitrosative stress. Because ascorbate scavenges reactive nitrogen and oxygen species, we studied the effect of ascorbate supplementation on iNOS expression as well as the neuronal and glial structural changes associated with gp120 exposure.
Human CNS cultures were derived from 16–18 week gestation post-mortem fetal brain. Cultures were incubated with 400 μM ascorbate-2-O-phosphate (Asc-p) or vehicle for 18 hours then exposed to 1 nM gp120 for 24 hours. The expression of iNOS and neuronal (MAP2) and astrocytic (GFAP) structural proteins was examined by immunohistochemistry and immunofluorescence using confocal scanning laser microscopy (CSLM).
Following gp120 exposure iNOS was markedly upregulated from undetectable levels at baseline. Double label CSLM studies revealed astrocytes to be the prime source of iNOS with rare neurons expressing iNOS. This upregulation was attenuated by the preincubation with Asc-p, which raised the intracellular concentration of ascorbate. Astrocytic hypertrophy and neuronal injury caused by gp120 were also prevented by preincubation with ascorbate.
Ascorbate supplementation prevents the deleterious upregulation of iNOS and associated neuronal and astrocytic protein expression and structural changes caused by gp120 in human brain cell cultures.
Url:
DOI: 10.1186/1742-2094-1-8
PubMed: 15285794
PubMed Central: 483061
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000340
Links to Exploration step
PMC:483061Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity</title><author><name sortKey="Walsh, Kimberley A" sort="Walsh, Kimberley A" uniqKey="Walsh K" first="Kimberley A" last="Walsh">Kimberley A. Walsh</name><affiliation wicri:level="1"><nlm:aff id="I1">Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation></author><author><name sortKey="Megyesi, Joseph F" sort="Megyesi, Joseph F" uniqKey="Megyesi J" first="Joseph F" last="Megyesi">Joseph F. Megyesi</name><affiliation wicri:level="1"><nlm:aff id="I1">Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">Department Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation></author><author><name sortKey="Wilson, John X" sort="Wilson, John X" uniqKey="Wilson J" first="John X" last="Wilson">John X. Wilson</name><affiliation wicri:level="1"><nlm:aff id="I3">Department Physiology, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department Physiology, University of Western Ontario, London, ON</wicri:regionArea></affiliation></author><author><name sortKey="Crukley, Jeff" sort="Crukley, Jeff" uniqKey="Crukley J" first="Jeff" last="Crukley">Jeff Crukley</name><affiliation wicri:level="1"><nlm:aff id="I1">Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation></author><author><name sortKey="Laubach, Victor E" sort="Laubach, Victor E" uniqKey="Laubach V" first="Victor E" last="Laubach">Victor E. Laubach</name><affiliation wicri:level="1"><nlm:aff id="I4">Department of Surgery, University of Virginia Health System, Charlottesville, VA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Surgery, University of Virginia Health System, Charlottesville, VA</wicri:regionArea></affiliation></author><author><name sortKey="Hammond, Robert R" sort="Hammond, Robert R" uniqKey="Hammond R" first="Robert R" last="Hammond">Robert R. Hammond</name><affiliation wicri:level="1"><nlm:aff id="I1">Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">Department Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">15285794</idno><idno type="pmc">483061</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC483061</idno><idno type="RBID">PMC:483061</idno><idno type="doi">10.1186/1742-2094-1-8</idno><date when="2004">2004</date><idno type="wicri:Area/Pmc/Corpus">000340</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000340</idno><idno type="wicri:Area/Pmc/Curation">000340</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000340</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity</title><author><name sortKey="Walsh, Kimberley A" sort="Walsh, Kimberley A" uniqKey="Walsh K" first="Kimberley A" last="Walsh">Kimberley A. Walsh</name><affiliation wicri:level="1"><nlm:aff id="I1">Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation></author><author><name sortKey="Megyesi, Joseph F" sort="Megyesi, Joseph F" uniqKey="Megyesi J" first="Joseph F" last="Megyesi">Joseph F. Megyesi</name><affiliation wicri:level="1"><nlm:aff id="I1">Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">Department Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation></author><author><name sortKey="Wilson, John X" sort="Wilson, John X" uniqKey="Wilson J" first="John X" last="Wilson">John X. Wilson</name><affiliation wicri:level="1"><nlm:aff id="I3">Department Physiology, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department Physiology, University of Western Ontario, London, ON</wicri:regionArea></affiliation></author><author><name sortKey="Crukley, Jeff" sort="Crukley, Jeff" uniqKey="Crukley J" first="Jeff" last="Crukley">Jeff Crukley</name><affiliation wicri:level="1"><nlm:aff id="I1">Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation></author><author><name sortKey="Laubach, Victor E" sort="Laubach, Victor E" uniqKey="Laubach V" first="Victor E" last="Laubach">Victor E. Laubach</name><affiliation wicri:level="1"><nlm:aff id="I4">Department of Surgery, University of Virginia Health System, Charlottesville, VA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Surgery, University of Virginia Health System, Charlottesville, VA</wicri:regionArea></affiliation></author><author><name sortKey="Hammond, Robert R" sort="Hammond, Robert R" uniqKey="Hammond R" first="Robert R" last="Hammond">Robert R. Hammond</name><affiliation wicri:level="1"><nlm:aff id="I1">Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">Department Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, London, ON</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of Neuroinflammation</title><idno type="eISSN">1742-2094</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>The pathogenesis of HIV-1 glycoprotein 120 (gp120) associated neuroglial toxicity remains unresolved, but oxidative injury has been widely implicated as a contributing factor. In previous studies, exposure of primary human central nervous system tissue cultures to gp120 led to a simplification of neuronal dendritic elements as well as astrocytic hypertrophy and hyperplasia; neuropathological features of HIV-1-associated dementia. Gp120 and proinflammatory cytokines upregulate inducible nitric oxide synthase (iNOS), an important source of nitric oxide (NO) and nitrosative stress. Because ascorbate scavenges reactive nitrogen and oxygen species, we studied the effect of ascorbate supplementation on iNOS expression as well as the neuronal and glial structural changes associated with gp120 exposure.</p></sec><sec sec-type="methods"><title>Methods</title><p>Human CNS cultures were derived from 16–18 week gestation post-mortem fetal brain. Cultures were incubated with 400 μM ascorbate-2-O-phosphate (Asc-p) or vehicle for 18 hours then exposed to 1 nM gp120 for 24 hours. The expression of iNOS and neuronal (MAP2) and astrocytic (GFAP) structural proteins was examined by immunohistochemistry and immunofluorescence using confocal scanning laser microscopy (CSLM).</p></sec><sec><title>Results</title><p>Following gp120 exposure iNOS was markedly upregulated from undetectable levels at baseline. Double label CSLM studies revealed astrocytes to be the prime source of iNOS with rare neurons expressing iNOS. This upregulation was attenuated by the preincubation with Asc-p, which raised the intracellular concentration of ascorbate. Astrocytic hypertrophy and neuronal injury caused by gp120 were also prevented by preincubation with ascorbate.</p></sec><sec><title>Conclusions</title><p>Ascorbate supplementation prevents the deleterious upregulation of iNOS and associated neuronal and astrocytic protein expression and structural changes caused by gp120 in human brain cell cultures.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-title>Journal of Neuroinflammation</journal-title><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15285794</article-id><article-id pub-id-type="pmc">483061</article-id><article-id pub-id-type="publisher-id">1742-2094-1-8</article-id><article-id pub-id-type="doi">10.1186/1742-2094-1-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Walsh</surname><given-names>Kimberley A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kim_walsh41@hotmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Megyesi</surname><given-names>Joseph F</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>jmegyesi@uwo.ca</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Wilson</surname><given-names>John X</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>john.wilson@fmd.uwo.ca</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Crukley</surname><given-names>Jeff</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>j_crukley@hotmail.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Laubach</surname><given-names>Victor E</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>vel8n@virginia.edu</email></contrib><contrib id="A6" corresp="yes" contrib-type="author"><name><surname>Hammond</surname><given-names>Robert R</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>rhammond@uwo.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Pathology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</aff><aff id="I2"><label>2</label>Department Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, London, ON, Canada</aff><aff id="I3"><label>3</label>Department Physiology, University of Western Ontario, London, ON, Canada</aff><aff id="I4"><label>4</label>Department of Surgery, University of Virginia Health System, Charlottesville, VA, USA</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>27</day><month>5</month><year>2004</year></pub-date><volume>1</volume><fpage>8</fpage><lpage>8</lpage><ext-link ext-link-type="uri" xlink:href="http://www.jneuroinflammation.com/content/1/1/8"></ext-link><history><date date-type="received"><day>12</day><month>4</month><year>2004</year></date><date date-type="accepted"><day>27</day><month>5</month><year>2004</year></date></history><permissions><copyright-statement>Copyright © 2004 Walsh et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Walsh et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder></permissions><abstract><sec><title>Background</title><p>The pathogenesis of HIV-1 glycoprotein 120 (gp120) associated neuroglial toxicity remains unresolved, but oxidative injury has been widely implicated as a contributing factor. In previous studies, exposure of primary human central nervous system tissue cultures to gp120 led to a simplification of neuronal dendritic elements as well as astrocytic hypertrophy and hyperplasia; neuropathological features of HIV-1-associated dementia. Gp120 and proinflammatory cytokines upregulate inducible nitric oxide synthase (iNOS), an important source of nitric oxide (NO) and nitrosative stress. Because ascorbate scavenges reactive nitrogen and oxygen species, we studied the effect of ascorbate supplementation on iNOS expression as well as the neuronal and glial structural changes associated with gp120 exposure.</p></sec><sec sec-type="methods"><title>Methods</title><p>Human CNS cultures were derived from 16–18 week gestation post-mortem fetal brain. Cultures were incubated with 400 μM ascorbate-2-O-phosphate (Asc-p) or vehicle for 18 hours then exposed to 1 nM gp120 for 24 hours. The expression of iNOS and neuronal (MAP2) and astrocytic (GFAP) structural proteins was examined by immunohistochemistry and immunofluorescence using confocal scanning laser microscopy (CSLM).</p></sec><sec><title>Results</title><p>Following gp120 exposure iNOS was markedly upregulated from undetectable levels at baseline. Double label CSLM studies revealed astrocytes to be the prime source of iNOS with rare neurons expressing iNOS. This upregulation was attenuated by the preincubation with Asc-p, which raised the intracellular concentration of ascorbate. Astrocytic hypertrophy and neuronal injury caused by gp120 were also prevented by preincubation with ascorbate.</p></sec><sec><title>Conclusions</title><p>Ascorbate supplementation prevents the deleterious upregulation of iNOS and associated neuronal and astrocytic protein expression and structural changes caused by gp120 in human brain cell cultures.</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000340 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000340 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:483061
|texte= Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:15285794" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |